Flow Pharma, Inc. en OncoImmunity AS werken samen voor ontwikkeling van FlowVaxTM gepersonaliseerde kankervaccins
Flow Pharma is nu een volwaardig biotechbedrijf in de neo-antigeenruimte
OSLO, Noorwegen-(BUSINESS WIRE)- Flow Pharma Inc., een biotechnologiebedrijf uit San Francisco Bay gericht op de ontwikkeling van gepersonaliseerde kankervaccins, heeft een samenwerking aangekondigd met het Noorse bioinformaticabedrijf OncoImmunity AS.
Deze persmededeling bevat multimedia. Bekijk hier het volledige persbericht: https://www.businesswire.com/news/home/20190312005768/en
In het kader van de overeenkomst zal OncoImmunity de Immuneoprofiler™-software in licentie verstrekken aan Flow Pharma ter ondersteuning van de klinische ontwikkeling en commercialisatie van producten op basis van het FlowVax-platform. De Immuneoprofiler™ heeft onlangs de CE-IVD-markering ontvangen als medisch hulpmiddel en vult enkele van de belangrijkste gaten in de neo-antigeenvoorspelling op. Het FlowVax-vaccinplatform, ontwikkeld door Flow Pharma, is geoptimaliseerd om gelijktijdig meerdere neo-antigeenpeptidetargets te leveren om de tumorspecifieke dodelijke T-cel aanval te verbeteren. OncoImmunity zal een op maat gemaakte machine learning-laag ontwikkelen, gebruikmakend van klinische data gegenereerd door Flow Pharma. Deze zal synchroon werken met de Immuneoprofiler™-software om voorspellingen op maat te maken voor het FlowVax-platform.
Flow Pharma, Inc. and OncoImmunity AS partner for the Development of FlowVaxTM Personalized Cancer Vaccines
Flow Pharma is now a full-stack biotech company in the neoantigen space
OSLO, Norway–(BUSINESS WIRE)– Flow Pharma Inc., a San Francisco Bay Area biotechnology company focused on developing personalized cancer vaccines, today announced a collaboration with Norwegian bioinformatics company OncoImmunity AS.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190312005768/en/
Under the agreement OncoImmunity will license the Immuneoprofiler™ software to Flow Pharma to support the clinical development and commercialisation of products based on the FlowVax platform. The Immuneoprofiler™ has recently received the CE-IVD mark certification as a medical device, and fills some of the key gaps in neoantigen prediction. The FlowVax vaccine platform developed by Flow Pharma, is optimized to simultaneously deliver multiple neoantigen peptide targets to enhance tumor-specific killer T-cell attack. OncoImmunity will develop a customised machine-learning layer, using clinical data generated by Flow Pharma, that will work-in-sync with the Immuneoprofiler™ software to make predictions tailored to the FlowVax platform.
“This exciting partnership and licensing deal represents a fantastic opportunity for OncoImmunity to apply its Immuneoprofiler™ prediction software to the FlowVax technology in a clinical setting. It also affords OncoImmunity the opportunity to leverage its in-depth knowledge of immune-informatics and expertise in machine learning to develop a customised solution for the FlowVax platform that will support Flow Pharma’s needs now and in the years ahead” said Richard Stratford., Chief Executive Officer at OncoImmunity.
“We believe that OncoImmunity’s Immuneoprofiler™ software represents the best-in-class solution for predicting clinically relevant bona fide neoantigens. Flow Pharma’s bioinformatics team will be working closely with OncoImmunity AS to customize the way we utilize Immuneoprofiler™ in order to optimize the use of the data we will be generating” said Reid Rubsamen, M.D., CEO of Flow Pharma.
About OncoImmunity
OncoImmunity AS is a machine-learning company offering a proprietary technology to address key knowledge gaps in the prediction of bona fide immunogenic neoantigen for personalized cancer immunotherapy. OncoImmunity’s software facilitates effective patient selection for cancer immunotherapy and identifies neoantigen targets creating truly personalized cancer vaccines & cell therapies in clinically actionable time-frames.
About Flow Pharma
Flow Pharma Inc. is a San Francisco Bay Area based, biotechnology company developing personalized neoantigen-based vaccines based on its proprietary FlowVax vaccine platform.
The FlowVax platform is optimized to simultaneously deliver multiple neoantigen peptide targets to enhance tumor-specific killer T-cell attack. Each of the chemical components used in the FlowVax platform are currently part of an FDA approved vaccine or pharmaceutical, simplifying the regulatory pathway. Flow Pharma is now gearing up to test therapeutic cancer vaccines based on the FlowVax platform.
About FlowVaxTM
Each of the chemical components used in the FlowVax platform are currently part of an FDA approved vaccine or pharmaceutical, simplifying the regulatory pathway. FlowVax vaccines can also be manufactured quickly and efficiently, keeping the cost down and getting the therapy in the hands of treating physicians soon after the diagnosis is made, for maximum efficacy.
However, as with all personalized vaccine approaches, the successful development and commercialisation of products based on the FlowVax platform is predicated on being able to identify clinically actionable and immunogenic neoantigen targets in a cost effective and clinically actionable time-frame. OncoImmunity’s Immuneoprofiler™ software, addresses this challenge, by harnessing the power of artificial intelligence (AI) to identify clinically relevant and immunogenic neoantigens from next generation sequencing data.
Forward Looking Statements
This press release may contain forward-looking statements, including information about management’s view of Flow Pharma, Inc. (”the Company”), future expectations, plans and prospects. In particular, when used in the preceding discussion, the words ”believes,””expects,””intends,””plans,””anticipates,” or ”may,” and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this presentation other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this presentation are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by Flow Pharma, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190312005768/en/
Contacts
Trevor Clancy Ph.D.
CSO OncoImmunity
E-mail: trevor@oncoimmunity.com
Phone: + 47 41 43 12 42